Ropeginterferon alfa-2b (Besremi)

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Essential Thrombocythemia, Polycythemia Vera

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Myelofibrosis · Phase 3 · investigational in the US

Also approved (2)
JP
  • Treatment of polycythaemia vera (use only when conventional therapies are not sufficiently effective or inappropriate)
Product first approved 2023PMDA
EU
  • Besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.
Product first approved 2019EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (8)
Essential Thrombocythemia
Myelofibrosis
NCT06468033 · PharmaEssentia
2025-07-18 – 2029-01-11 · Primary Myelofibrosis, Myeloproliferative Neoplasm
What this study did
Polycythemia Vera
NCT04655092 · PharmaEssentia Japan K.K.
2021-01-19 – 2026-06-30 · Polycythemia Vera (PV)
What this study did
NCT06002490 · PharmaEssentia Japan K.K.
2023-10-17 – 2024-07-26 · Polycythemia Vera (PV)
What this study did
Other / comorbidity
NCT06514807 · AOP Orphan Pharmaceuticals AG
2023-12-04 – 2028-03-15 · Essential Thrombocythaemia
What this study did
NCT05770466 · National Taiwan University Hospital
2022-04-01 – 2023-01-11 · COVID-19
What this study did
NCT04382937 · PharmaEssentia
2016-01-12 – 2020-07-15 · Chronic Hepatitis C Virus Infection
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT05808322 · National Taiwan University Hospital
2023-05-15 – 2024-12-31 · COVID-19
What this study did
Phase 2 (11)
Essential Thrombocythemia
NCT05482971 · PharmaEssentia
2022-09-29 – 2027-03-31 · Essential Thrombocythemia
What this study did
Myelofibrosis
NCT06770842 · The University of Hong Kong
2025-03-01 – 2027-12 · Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
What this study did
NCT05731245 · National Taiwan University Hospital
2023-02-08 – 2026-10-12 · Pre-fibrotic Myelofibrosis
What this study did
NCT04988815 · The University of Hong Kong
2021-09-01 – 2025-12-31 · Primary Myelofibrosis, Prefibrotic Stage, Myelofibrosis
What this study did
NCT02370329 · Mayo Clinic
2015-08-12 – 2023-11-30 · Primary Myelofibrosis, Secondary Myelofibrosis
What this study did
Polycythemia Vera
NCT05485948 · PharmaEssentia
2021-10-08 – 2027-07 · Polycythemia Vera
What this study did
NCT04182100 · PharmaEssentia Japan K.K.
2019-12-20 – 2021-03-08 · Polycythemia Vera (PV)
What this study did
Other / comorbidity
NCT07468916 · Jonsson Comprehensive Cancer Center
2027-01-30 – 2033-01-30 · Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
What this study did
NCT07269470 · M.D. Anderson Cancer Center
2026-07-13 – 2029-11-01 · Chronic Myeloid Leukemia
What this study did
NCT05467553 · National Taiwan University Hospital
2023-02-24 – 2025-08-31 · Hepatitis D
What this study did
NCT01587586 · PharmaEssentia
2011-10-18 – 2016-11-22 · Hepatitis C, Chronic
What this study did
Phase 1/2 (3)
Polycythemia Vera
Other / comorbidity
NCT07646821 · M.D. Anderson Cancer Center
2026-10-27 – 2030-12-11 · Ropeginterferon, Alfa-2b, Azacitidine, MDS/AML
What this study did
NCT04233840 · National Taiwan University Hospital
2019-02-12 – 2023-07-31 · Hepatocellular Carcinoma
What this study did
Phase 1 (8)
Myelofibrosis
NCT07521046 · University of Utah
2026-08-21 – 2030-08 · Myelofibrosis
What this study did
Other / comorbidity
NCT07053904 · PharmaEssentia
2025-04-21 – 2029-12-31 · Advanced Solid Tumors
What this study did
NCT07047885 · H. Lee Moffitt Cancer Center and Research Institute
2025-08-27 – 2028-06 · Cutaneous T Cell Lymphoma
What this study did
NCT04638439 · PharmaEssentia
2022-08-17 – 2026-04-08 · Chronic Hepatitis B Infection, Chronic Hepatitis D Infection
What this study did
NCT04774107 · PharmaEssentia
2020-11-26 – 2022-07-18 · Hepatitis C, Chronic
What this study did
NCT03546465 · PharmaEssentia Japan K.K.
2018-05-07 – 2019-07-15 · Healthy Volunteers
What this study did
NCT01933906 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2013-08-30 – 2018-11-14 · Chronic Phase Chronic Myeloid Leukemia
What this study did
NCT05129644 · PharmaEssentia
2009-11-07 – 2010-06-26 · Healthy Volunteers
What this study did
Phase 4 (1)
Polycythemia Vera
NCT06290765 · PharmaEssentia
2026-08-01 – 2027-06-30 · Polycythemia Vera, Myeloproliferative Neoplasm
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT05494528 · National Taiwan University Hospital
2021-05-04 – 2024-12-30 · Chronic Hepatitis B Virus Infection
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2/3 (1)
Polycythemia Vera
NCT07722611 · Merck Sharp & Dohme LLC
2026-10-29 – 2032-11-30 · Polycythemia Vera
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Essential Thrombocythemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ropeginterferon Alfa-2b (Besremi): this drugApprovedProtein / enzyme therapeuticType I interferon receptorPartial signal
NCT04285086: Durable modified ELN response at months 9 and 12: 39 (43%) of 91 ropeginterferon alfa-2b vs five (6%) of 83 anagrelide
Interferon Alfa-2b (Intron A)
Approved(overall)
Biologic (subtype unspecified)Type I interferon receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Interferon Beta-1b
Approved(overall)
Biologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Peginterferon Alfa-2a (Pegasys)
Approved(overall)
—Type I interferon receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Peginterferon Beta-1a (Plegridy)
Approved(overall)
Biologic (subtype unspecified)Type I interferon receptor, Interferon beta receptor (type I IFN signaling)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Rebif (interferon Beta 1a)
Approved(overall)
Biologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
BomedemstatPhase 3Small moleculeLSD1 (lysine-specific demethylase 1)not yet gradedNo reviewed efficacy summary in this indication
INCA033989Phase 3Monoclonal antibodymutant calreticulin (mutCALR)not yet gradedNo reviewed efficacy summary in this indication
Human Serum Albumin / Interferon Alpha2b Fusion Protein
Phase 1/2(overall)
Biologic (subtype unspecified)Type I interferon receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Interferon-Beta1
—(overall)
Biologic (subtype unspecified)Type I interferon receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ropeginterferon alfa-2b (Besremi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2MyelofibrosisRecruiting
Est. primary completion 2026-12 · NCT06770842 · CT.gov ↗
What to watch
2027 (1)
November 2027 (1)
Phase 3MyelofibrosisActive not recruiting
Est. primary completion 2027-11-18 · NCT06468033 · CT.gov ↗
What to watch
2028 (4)
March 2028 (1)
Phase 3Essential ThrombocythaemiaActive not recruiting
Est. primary completion 2028-03-15 · NCT06514807 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1Cutaneous T Cell LymphomaRecruiting
Est. primary completion 2028-06 · NCT07047885 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1/2Ropeginterferon, Alfa-2b, Azacitidine, MDS/AMLRecruiting
Est. primary completion 2028-12-11 · NCT07646821 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsEnrolling by invitation
Est. primary completion 2028-12-31 · NCT07053904 · CT.gov ↗
What to watch
2029 (2)
August 2029 (1)
Phase 1MyelofibrosisRecruiting
Est. primary completion 2029-08 · NCT07521046 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Chronic Myeloid LeukemiaRecruiting
Est. primary completion 2029-11-01 · NCT07269470 · CT.gov ↗
What to watch
2032 (1)
January 2032 (1)
Phase 2Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm …Not yet recruiting
Est. primary completion 2032-01-30 · NCT07468916 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 August 2026ApprovalFDA Boxed Warning on Besremi (BLA761166)
US, FDA · FDA · Source ↗